Molecular Partners Management

Management criteria checks 2/4

Molecular Partners' CEO is Patrick Amstutz, appointed in Jan 2004, has a tenure of 20.83 years. total yearly compensation is CHF1.05M, comprised of 36.8% salary and 63.2% bonuses, including company stock and options. directly owns 1.99% of the company’s shares, worth €3.82M. The average tenure of the management team and the board of directors is 3.3 years and 4.6 years respectively.

Key information

Patrick Amstutz

Chief executive officer

CHF 1.0m

Total compensation

CEO salary percentage	36.8%
CEO tenure	20.8yrs
CEO ownership	2.0%
Management average tenure	3.3yrs
Board average tenure	4.6yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Patrick Amstutz's remuneration changed compared to Molecular Partners's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2024	n/a	n/a	-CHF 63m
Jun 30 2024	n/a	n/a	-CHF 58m
Mar 31 2024	n/a	n/a	-CHF 59m
Dec 31 2023	CHF 1m	CHF 385k	-CHF 62m
Sep 30 2023	n/a	n/a	-CHF 60m
Jun 30 2023	n/a	n/a	-CHF 62m
Mar 31 2023	n/a	n/a	-CHF 50m
Dec 31 2022	CHF 1m	CHF 383k	CHF 118m
Sep 30 2022	n/a	n/a	CHF 117m
Jun 30 2022	n/a	n/a	CHF 118m
Mar 31 2022	n/a	n/a	CHF 106m
Dec 31 2021	CHF 1m	CHF 380k	-CHF 64m
Sep 30 2021	n/a	n/a	-CHF 67m
Jun 30 2021	n/a	n/a	-CHF 72m
Mar 31 2021	n/a	n/a	-CHF 66m
Dec 31 2020	CHF 1m	CHF 380k	-CHF 63m
Sep 30 2020	n/a	n/a	-CHF 53m
Jun 30 2020	n/a	n/a	-CHF 48m
Mar 31 2020	n/a	n/a	-CHF 43m
Dec 31 2019	CHF 930k	CHF 363k	-CHF 36m
Sep 30 2019	n/a	n/a	-CHF 37m
Jun 30 2019	n/a	n/a	-CHF 38m
Mar 31 2019	n/a	n/a	-CHF 38m
Dec 31 2018	CHF 909k	CHF 346k	-CHF 37m
Sep 30 2018	n/a	n/a	-CHF 27m
Jun 30 2018	n/a	n/a	-CHF 18m
Mar 31 2018	n/a	n/a	-CHF 24m
Dec 31 2017	CHF 885k	CHF 344k	-CHF 25m

Compensation vs Market: Patrick's total compensation ($USD1.18M) is above average for companies of similar size in the German market ($USD790.61K).

Compensation vs Earnings: Patrick's compensation has increased whilst the company is unprofitable.

CEO

Patrick Amstutz (49 yo)

20.8yrs

Tenure

CHF 1,047,000

Compensation

Dr. Patrick Amstutz, Ph.D. is a Co-Founder of Molecular Partners AG and has been its Chief Executive Officer since November 2016 and serves as its Member of Management Board since 2004. Dr. Amstutz serves...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Patrick Amstutz	Co-Founder	20.8yrs	CHF 1.05m	1.99% € 3.8m
Michael Stumpp	Co-Founder	20.8yrs	no data	2.08% € 4.0m
Robert Hendriks	Senior VP of Finance	5.3yrs	no data	no data
Alexander Zurcher	COO & Member of Management Board	2.3yrs	no data	0.070% € 133.5k
Renate Gloggner	Executive VP of People & Community and Member of Management Board	2.9yrs	no data	0.062% € 119.4k
Daniel Steiner	Senior Vice President of Research & Technology	3.7yrs	no data	no data
Seth Lewis	Senior Vice President of Investor Relations	no data	no data	no data
Michael Pitzner	General Counsel	2yrs	no data	no data
Pamela Trail	Strategic Consultant	5.3yrs	no data	no data
Anne Goubier	Senior Vice President of Research & Early Development	2.8yrs	no data	no data
Philippe Legenne	Chief Medical Officer	1.3yrs	no data	no data

3.3yrs

Average Tenure

52yo

Average Age

Experienced Management: 6ML0's management team is considered experienced (3.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Patrick Amstutz	Co-Founder	7.1yrs	CHF 1.05m	1.99% € 3.8m
Steven H. Holtzman	Independent Non Executive Director	10.5yrs	CHF 135.00k	0.040% € 76.4k
William A. Burns	Independent Chairman of the Board	7.1yrs	CHF 295.00k	0.073% € 139.9k
Vito Palombella	Independent Director	4.6yrs	CHF 125.00k	0.0095% € 18.2k
Agnete Fredriksen	Independent Director	3.6yrs	CHF 125.00k	no data
Michael Vasconcelles	Independent Director	4.6yrs	CHF 135.00k	0.0095% € 18.2k
Sandip Kapadia	Independent Director	4.6yrs	CHF 130.00k	0.0095% € 18.2k
Dominik Hochli	Independent Director	3.6yrs	CHF 133.00k	no data

4.6yrs

Average Tenure

59yo

Average Age

Experienced Board: 6ML0's board of directors are considered experienced (4.6 years average tenure).

Molecular Partners Management

Management criteria checks 2/4

Key information

Recent management updates

Molecular Partners AG, Annual General Meeting, Apr 17, 2024

Molecular Partners AG Announces Executive Changes

Molecular Partners AG, Annual General Meeting, Apr 04, 2023

Recent updates

Molecular Partners AG Presents Preclinical Proof-Of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024

Molecular Partners AG has completed a Follow-on Equity Offering in the amount of $20.000004 million.

Molecular Partners AG has filed a Follow-on Equity Offering in the amount of $20.000004 million.

Molecular Partners Announces the Debut of their Lead Radio-Darpin Therapy (RDT) Candidate MP0712, Targeting DLL3

Molecular Partners AG Presents Positive Data from Completed Phase 1 Trial of MP0317 (FAP X CD40 DARPin) Monotherapy in Patients with Advanced Solid Tumors At ASCO 2024

Molecular Partners AG Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533's Proposed Mechanism of Action

Molecular Partners AG to Report First Half, 2024 Results on Aug 26, 2024

Molecular Partners AG, Annual General Meeting, Apr 17, 2024

Molecular Partners AG to Report Fiscal Year 2023 Final Results on Mar 14, 2024

Molecular Partners AG Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2A Trial of Mp0533 for Patients with Relapsed/Refractory AML and AML/MDS At ASH Annual Meeting

Molecular Partners AG Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 SITC Annual Meeting

Molecular Partners Ag to Present Initial Data from Ongoing Phase 1/2A Trial of Mp0533 for Patients with Relapsed/Refractory Aml and Aml/Mds At the 65Th Ash Annual Meeting and Exposition

Molecular Partners AG Announces Executive Changes

Molecular Partners Initiates Clinical Study of Trispecific Candidate Mp0533 for the Treatment of Acute Myeloid Leukemia

Molecular Partners AG Presents New Preclinical Data Supporting its MP0533 DARPin T-Cell Engager for the Treatment of AML

Molecular Partners AG Presents Positive Interim Safety and Mechanistic Data from Ongoing Phase 1 Trial of MP0317 for Treatment of Solid Tumors

Molecular Partners AG Announces Continued Progress Across Oncology Programs with First Clinical Data Expected from Phase 1 Trial of MP0317 and Initiation of Phase 1 Trial of MP0533 Anticipated by Year-End

Molecular Partners AG, Annual General Meeting, Apr 04, 2023

Johnson Fistel Files A Class Action Complain Against Molecular Partners AG

Molecular Partners AG Announces Publication in Nature Biotechnology Detailing Design and Mechanism of Ensovibep DARP in Antiviral for SARS-CoV-2

Pomerantz Law Firm Announces the Filing of A Class Action Against Molecular Partners Ag and Certain Officers and Directors – Moln

Molecular Partners AG Announces Emergency Use Authorization Request for Ensovibep Submitted to the US Food and Drug Administration for the Treatment of Covid-19

Novartis and Molecular Partners Report Positive Topline Data from Phase 2 Study for ensovibep (MP0420), a DARPin Antiviral Therapeutic for COVID-19

Molecular Partners Confirms Ensovibep Retains Neutralization of Omicron Variant of SARS-CoV-2 in Preclinical Studies

Molecular Partners Presents Results from a Phase 2a Trial of Ensovibep in 12 COVID-19 Patients

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age